

### III. CLAIMS

1. (Currently Amended) A polynucleotide directed towards a gene of a catalytic subunit of human telomerase, wherein ~~characterized in that the~~ polynucleotide specifically binds ~~interacts~~ with the mRNA of the catalytic subunit of human telomerase in a at least two target sequence regions region selected from the group consisting of region 2206-2225 (SEQ. ID NO 4) and region 2331-2350 (SEQ. ID NO 8), inhibits human telomerase expression and where the oligonucleotide is an antisense oligonucleotide complementary to such regions. ~~2176 to 2250 (SEQ ID NO:1) as well as that of 2296-2393 (SEQ ID NO:2) in accordance with accession number AF015950.~~
2. (Currently Amended) The polynucleotide according to claim 1, wherein the polynucleotide interacts with target sequence regions selected from the group consisting of SEQ ID NO 10 and SEQ ID NO 13. ~~comprising 2183-2205, 2206-2225, SEQ ID NO:4) 2315-2334, 2317-2336, 2324-2346, and/or 2331-2350 SEQ ID NO:8 and/or 2333-2352.~~
3. Cancelled
4. (Currently Amended) The polynucleotide according to claim 1, wherein the polynucleotide is immobilized on a carrier selected from the group consisting of porous gels, aluminum oxide, bentonite, agarose, starch, nylon and polyacrylamide.

5-7. Cancelled

8. (Currently Amended) The polynucleotide according to ~~claim~~  
7 claim 1, wherein the antisense oligonucleotide is  
modified by phosphothioate bonds ~~and/or other chemical~~  
~~modifications~~.

9. Cancelled

10. (Currently Amended) A ~~pharmaceutical~~ composition  
comprising a polynucleotide according to claim ~~claims~~ 1  
in combination with a pharmaceutically tolerable carrier.

11. (Previously Presented) A kit comprising: a polynucleotide  
according to claim 1 and a pharmaceutically tolerable  
carrier.

12. Cancelled

13. (Withdrawn) Method for diagnosis, prophylaxis, therapy,  
follow-up and/or aftercare of diseases associated with  
cell growth, differentiation and/or division, comprising  
using a polynucleotide according to claim 1, optionally  
in combination with a pharmaceutically tolerable carrier.

14. (Withdrawn) The method according to the preceding claim,  
wherein the disease is a tumor.

15. (Withdrawn) The method according to claim 14, wherein the  
tumor is a solid tumor or a leukemia.

16. (Withdrawn) The method according to claim 15, wherein the solid tumor is a tumor of the urogenital tract and/or gastrointestinal tract.
17. Canceled.
18. Canceled.
19. (Withdrawn) The method according to claim 16, wherein the tumor of the urogenital tract is a bladder carcinoma and/or a metastase of said tumor.
20. (Withdrawn) The method according to claim 13, wherein the follow-up is monitoring the effectiveness of an anti-tumor treatment.
21. (Withdrawn) The method according to claims 13 wherein the polynucleotide is used in a combination therapy.
22. Canceled.
23. (Withdrawn) The method according to claim 22, wherein the combination therapy comprises an adjuvant biologically specified form of therapy.
24. (Withdrawn) The method according to claim 23, wherein said form of therapy is an immune therapy.
25. (Withdrawn) The method according to claims 21, wherein

the combination therapy is a gene therapy and/or a therapy using a polynucleotide against the same or other target molecule.

26. (Withdrawn) The method according to claims 13 for increasing the sensitivity of tumor cells to cytostatic agents and/or radiation.
27. (Withdrawn) Method for inhibiting the vitality, the proliferation rate of cells, for inducing apoptosis and/or cell cycle arrest comprising the step of using a polynucleotide according to claim 1.